Ptc Therapeutics (PTCT) Current Leases (2019 - 2026)

Ptc Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $12.1 million for Q1 2026.

• In Q1 2026, Current Leases rose 139.31% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $12.1 million (up 139.31% YoY), while the FY2025 annual figure was $12.5 million, up 20.47% from the prior year.
• Current Leases was $12.1 million for Q1 2026 at Ptc Therapeutics, down from $12.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $14.6 million in Q1 2024 to a low of $1.8 million in Q1 2022.
• Historically, Current Leases has averaged $6.1 million across 5 years, with a median of $3.0 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Current Leases plunged 70.65% in 2023, then jumped 684.71% in 2024.
• A 5-year view of Current Leases shows it stood at $3.0 million in 2022, then surged by 333.4% to $13.0 million in 2023, then slipped by 20.3% to $10.4 million in 2024, then advanced by 20.47% to $12.5 million in 2025, then retreated by 3.25% to $12.1 million in 2026.
• The last three Current Leases figures came in at $12.1 million (Q1 2026), $12.5 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.